Issue of Share Options
CelLBxHealth plc has announced the approval of up to 50,000,000 Share Options for employees, including 11,400,000 to Chief of Staff Michelle Munson, at an exercise price of 1.35 pence per Ordinary Share. These options are subject to a three-year vesting period, with one-third vesting after one year and the remainder vesting quarterly, contingent on continued employment and a share price performance target of 2.5p on 10 out of 20 consecutive trading days for the final portion. Following this issuance, the company will have outstanding options representing approximately 4.9% of its issued share capital.
Select text to share a quote on X · sign in to keep highlights & notes in your CLBX notes
Guildford, UK and Plymouth Meeting, U.S. - 16 July 2026 - CelLBxHealth plc (AIM: CLBX), a CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, announces that, the Nominations/Remuneration Committee has approved the issue of up to 50,000,000 Share Options under its existing share option plans to employees (the "Share Options") including 11,400,000 Share Options to Michelle Munson, Chief of Staff and a Person Discharging Managerial Responsibility ("PDMR").
Share Options are issued to align the interest of employees with shareholders and help motivate, reward and retain them. The allocation of Share Options approved by the Nominations/Remuneration Committee takes into account the significant contribution from the senior management team and wider staff to the task of delivering against the revised business strategy, and, in particular, to converting the commercial pipeline into sustainable revenue growth. This, in turn, would be expected to deliver increased shareholder value.
Following the issue of these options, the Company will have outstanding options over a total of up to 55,845,000 Ordinary Shares, representing approximately 4.9% of its issued and to be issued share capital.
The exercise price for the Share Options is 1.35 pence per Ordinary Share, the Company's closing mid-market share price per Ordinary Share on 15 July 2026, being the latest practicable date prior to this announcement. The Share Options are subject to certain service and/or performance conditions over a three-year period.
All of these Share Options have performance conditions as set out below:
- Time-based vesting: One-third (1/3) of the Share Options will vest on the first anniversary of the grant date. The remaining time-based options will then vest in equal quarterly instalments of one-twelfth (1/12) over the following two years.
- Performance-based vesting: The final portion of the Share Options (those scheduled to vest during quarters 7 to 12 after the grant date) will only vest if, in addition to the employee remaining continuously employed, the Company's share price closes at or above 2.5p on any 10 out of 20 consecutive trading days at any point before the end of the three-year period.
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Michelle Munson |
| 2 | Reason for the notification | |
| a) | Position/status | Chief of Staff |
| b) | Initial notification /Amendment | Initial notification |
| a) | Name | CelLBxHealth Plc |
| b) | LEI | 213800BY11K6W3NMS374 |
| a) | Description of the financial instrument, type of instrument | Ordinary shares of 0.05 pence value each |
| Identification code | GB0034330679 | |
| b) | Nature of the transaction | Options over ordinary shares of 0.05 pence each |
| c) | Price(s) and volume(s) | |
| Price(s) | Volume(s) | |
| 1.35 pence per share | Up to 11,400,000 dependent on share price performance | |
| d) | Aggregated information | |
| - Aggregated volume | n/a | |
| - Price | n/a | |
| e) | Date of the transaction | 16 July 2026 |
| f) | Place of the transaction | Off Market |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.